PMGC subsidiary Northstrive and MOA amend license milestones for BLS-M22, add amendment fee

PMGC Holdings Inc.

Third Amendment updates development milestones for human health field, including pre-clinical, IND, Phase 1-3, FDA marketing approval.
For BLS-M22, Phase 1 trial may be excused; milestone payment deferred to Phase 2 start.
PMGC to pay MOA a one-time amendment fee within 30 days of effective date (amount redacted).
Amendment effective as of March 24, 2026; signed by CEO Graydon Bensler and MOA COO Tiger Yoon.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

PMGC Holdings Inc. amended Third Amendment with MOA Life Plus Co., Ltd. (effective 2026-03-24).

Action: amendment
Agreement: license
Counterparty: MOA Life Plus Co., Ltd.
Effective: 2026-03-24

Exact text from the filing

Northstrive Biosciences Inc. (“Northstrive”), a wholly owned subsidiary of PMGC Holdings Inc. (the “Company”), entered into a Third Amendment to License Agreement (the “Third Amendment”) with MOA Life Plus Co., Ltd. (“MOA”), a corporation organized under the laws of the Republic of Korea.

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

PMGC Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-035098

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.